Tilray Brands, Inc. (TLRY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tilray Brands, Inc. (TLRY) trades at $4.67 with AI Score 47/100 (Grade C). Tilray Brands, Inc. is a global cannabis-lifestyle CPG company. Market cap: $522M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 6, 2026TLRY stock analysis for 2026: Analysts have set a consensus price target of $10.00 for Tilray Brands, Inc., suggesting 114.1% upside from the current price of $4.67. The AI MoonshotScore is 47/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
TLRY: the 3 scored disciplines are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Tilray Brands, Inc. (TLRY) Healthcare & Pipeline Overview
Tilray Brands, Inc. operates as a global cannabis-lifestyle CPG company, focusing on the research, cultivation, production, and distribution of medical and recreational cannabis products, beverage alcohol, and wellness products across Canada, the United States, Europe, and other international markets, positioning itself within the expanding global cannabis industry.
What Is the Investment Thesis for TLRY?
Tilray Brands, Inc. presents a multifaceted investment thesis predicated on its diversified business model and strategic positioning within the evolving cannabis and consumer packaged goods industries. Key value drivers include the expansion of its cannabis business in both medical and recreational markets, leveraging its established brands and distribution networks. The growth of its beverage alcohol segment, particularly through acquisitions like Breckenridge Distillery, offers diversification and revenue stability. A potential catalyst is the further legalization of cannabis in key markets, such as the United States and Europe, which could significantly expand Tilray's market access. However, investors may want to evaluate the risks associated with regulatory uncertainty, intense competition, and the company's current negative profit margin of -156.2%.
Based on FMP financials and quantitative analysis
TLRY Key Highlights
Tilray Brands operates in four segments: Cannabis, Distribution, Beverage Alcohol, and Wellness, diversifying its revenue streams.
- The company's gross margin stands at 27.7%, reflecting its ability to manage production costs and pricing strategies.
- Tilray's beta of 2.11 indicates higher volatility compared to the broader market, potentially offering higher returns but also greater risk.
- Tilray has a global presence, operating in Canada, the United States, Europe, Australia, and Latin America, reducing reliance on any single market.
- Tilray's diversified brand portfolio, including Tilray, Aphria, SweetWater, and Breckenridge Distillery, caters to a wide range of consumer preferences.
Who Are TLRY's Competitors?
TLRY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CGC Canopy Growth Corporation | $1.04 | +0.48% | $441M | 46 |
| ACB Aurora Cannabis Inc. | $3.81 | -2.56% | $236M | 55 |
| CRON Cronos Group Inc. | $3.22 | -2.13% | $1.20B | 62 |
| VREOF Vireo Growth Inc. | $10.84 | -1.20% | $415M | 62 |
| EMBC Embecta Corp. | $5.47 | +0.92% | $325M | 74 |
| COLL Collegium Pharmaceutical, Inc. | $27.54 | -4.18% | $893M | 74 |
| PCRX Pacira BioSciences, Inc. | $24.36 | +1.50% | $958M | 85 |
| AMPH Amphastar Pharmaceuticals, Inc. | $21.74 | +1.87% | $959M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TLRY's Key Strengths?
Diversified business model across cannabis, beverage alcohol, and wellness.
- Global presence and distribution network.
- Strong brand recognition in the cannabis industry.
- GMP-certified production facilities.
What Are TLRY's Weaknesses?
Negative profit margin.
- High beta indicating higher volatility.
- Dependence on regulatory changes in the cannabis industry.
- Intense competition in the cannabis and beverage alcohol markets.
What Could Drive TLRY Stock Higher?
TLRY catalyst: Potential federal legalization of cannabis in the United States, which could significantly expand Tilray's market access.
- Expansion of cannabis operations in Europe, Australia, and Latin America.
- Growth in the beverage alcohol segment through strategic acquisitions and organic growth.
- Development of new and innovative cannabis products.
What Are the Key Risks for TLRY?
Financial-distress signal — its Altman Z-Score of -1.92 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-8.0%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Regulatory uncertainty in the cannabis industry.
- Intense competition from other cannabis companies and beverage alcohol producers.
- Fluctuations in cannabis prices and demand.
- Product recalls or safety concerns.
- Negative profit margin impacting financial performance.
What Are the Growth Opportunities for TLRY?
- Expansion in the U.S. Cannabis Market: With potential federal legalization on the horizon, Tilray can leverage its existing infrastructure and brand recognition to rapidly expand its presence in the U.S. cannabis market. Timeline: Ongoing, with potential acceleration upon federal legalization.
- Growth in the Beverage Alcohol Segment: Tilray can continue to expand its beverage alcohol business through strategic acquisitions and organic growth of its existing brands, such as Breckenridge Distillery and SweetWater. The global alcoholic beverage market is a multi-billion dollar industry, providing ample opportunity for Tilray to increase its market share. Timeline: Ongoing.
- International Expansion in Cannabis: Tilray can further expand its cannabis operations in Europe, Australia, and Latin America, capitalizing on the increasing legalization and acceptance of cannabis in these regions. The international cannabis market is projected to experience significant growth in the coming years, offering substantial opportunities for Tilray. Timeline: Ongoing.
- Development of New Cannabis Products: Tilray can invest in research and development to create new and innovative cannabis products, catering to evolving consumer preferences and demands. This includes developing new edibles, topicals, and other cannabis-infused products. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Tilray can pursue strategic partnerships and acquisitions to expand its product portfolio, distribution network, and geographic reach. This includes partnering with other cannabis companies, beverage alcohol producers, and wellness product manufacturers. Timeline: Ongoing.
What Are TLRY's Competitive Advantages?
- Brand recognition and reputation in the cannabis industry.
- Global presence and distribution network.
- Diversified product portfolio across cannabis, beverage alcohol, and wellness.
- GMP-certified production facilities ensuring product quality and consistency.
What Does TLRY Do?
Tilray Brands, Inc., headquartered in Leamington, Canada, is a global cannabis-lifestyle consumer packaged goods company. Originally known as Tilray, Inc., the company has evolved through strategic mergers and acquisitions to broaden its portfolio beyond cannabis. Tilray's operations span across four key segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business focuses on the cultivation, production, marketing, and distribution of medical and adult-use cannabis products, including flowers, oils, vapes, edibles, and topicals. These products are GMP-certified, ensuring quality and consistency. The Distribution Business involves the purchase and resale of pharmaceutical and wellness products, expanding Tilray's reach into related markets. The Beverage Alcohol Business produces, markets, sells, and distributes a range of alcoholic beverages, diversifying Tilray's revenue streams. The Wellness Business focuses on hemp-based food and other wellness products, catering to health-conscious consumers. Tilray's products are marketed under a variety of brands, including Tilray, Aphria, Broken Coast, SweetWater, and Breckenridge Distillery. The company sells its products through various channels, including retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, governments, and direct to consumers, establishing a broad distribution network.
What Products and Services Does TLRY Offer?
- Researches and develops medical cannabis products.
- Cultivates and produces cannabis flowers, oils, vapes, edibles, and topicals.
- Markets and distributes medical and adult-use cannabis products.
- Purchases and resells pharmaceutical and wellness products.
- Produces, markets, and sells beverage alcohol products.
- Offers hemp-based food and other wellness products.
- Sells products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments.
- Sells products directly to consumers.
How Does TLRY Make Money?
- Cultivation and production of cannabis products for medical and recreational use.
- Distribution of cannabis, pharmaceutical, and wellness products through various channels.
- Production and sale of beverage alcohol products.
- Direct-to-consumer sales through online platforms and retail locations.
What Industry Does TLRY Operate In?
Tilray Brands operates within the rapidly evolving cannabis and consumer packaged goods industries. The beverage alcohol industry is a mature market, but Tilray's strategic acquisitions in this space provide diversification and access to established distribution channels. The competitive landscape includes other major cannabis companies, established beverage alcohol producers, and wellness product manufacturers. Tilray's diversified business model and global presence position it to capitalize on growth opportunities in these dynamic markets.
Who Are TLRY's Key Customers?
- Medical patients seeking cannabis for therapeutic purposes.
- Adult-use consumers seeking cannabis for recreational purposes.
- Retailers and wholesalers distributing cannabis products.
- Hospitals, pharmacies, and research institutions using cannabis for medical research and treatment.
- Consumers of beverage alcohol and wellness products.
Tilray Brands, Inc. (TLRY) Valuation Context
Valued at $522M, TLRY is classified as a small-cap stock. Relative to its peer group, TLRY's quantitative score of 47/100 is below the peer average of 60/100.
TLRY Revenue & Earnings Trend
In Q2 2026, TLRY generated $281.7M in top-line revenue, marking a sequential decrease of 0.2%. The company recorded a net loss of $49.6M, with diluted EPS of $-0.43. Revenue has contracted over three consecutive quarters, which investors in this small-cap Healthcare stock should monitor closely. Across the four most recent quarters, TLRY averaged $-0.33 in diluted EPS.
Company Profile
Tilray Brands, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Leamington, CA. The company is led by CEO Irwin David Simon. TLRY has traded publicly since 2018.
Key Financial Metrics
Return on equity for Tilray Brands, Inc. stands at -8.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -6.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -21.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.21 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -28.4%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Tilray Brands, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.92 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Tilray Brands, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 472.7% below estimates on average.
Forward Outlook
Wall Street analysts project Tilray Brands, Inc. revenue of about $878.0M for fiscal 2026, with EPS near $-0.64. The estimate reflects 7 contributing analysts.
TLRY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Diversified business model across cannabis, beverage alcohol, and wellness.
- Global presence and distribution network.
- Strong brand recognition in the cannabis industry.
- GMP-certified production facilities.
Bear Case
- Negative profit margin.
- High beta indicating higher volatility.
- Dependence on regulatory changes in the cannabis industry.
- Intense competition in the cannabis and beverage alcohol markets.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $282M | -$50M | -$0.43 |
| Q1 2026 | $282M | -$36M | -$0.33 |
| Q4 2025 | $304M | -$63M | -$0.57 |
| Q3 2025 | $288M | -$442,312 | -$0.0040 |
Based on FMP financials and quantitative analysis
TLRY Latest News
-
6 Health Care Stocks Whale Activity In Today’s Session
benzinga · Aug 3, 2026
-
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Market Exclusive · Aug 2, 2026
-
'THC And CBD From Marijuana Reduces Agitation In 9 Out Of 10 People With Alzheimer’s Or Other Dementia, Study Shows' - Marijuana Moment
benzinga · Jul 20, 2026
-
Is Tilray a Textbook Value Trap -- or the Most Undervalued Cannabis Stock on the Market?
Motley Fool · Jul 3, 2026
TLRY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TLRY.
Price Targets
Consensus target: $10.00
TLRY MoonshotScore
What does this score mean?
The MoonshotScore rates TLRY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
6 Health Care Stocks Whale Activity In Today’s Session
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
'THC And CBD From Marijuana Reduces Agitation In 9 Out Of 10 People With Alzheimer’s Or Other Dementia, Study Shows' - Marijuana Moment
Is Tilray a Textbook Value Trap -- or the Most Undervalued Cannabis Stock on the Market?
Latest Tilray Brands, Inc. Analysis
Leadership: Irwin David Simon
Chairman and Chief Executive Officer
Irwin D. Simon serves as the Chairman and Chief Executive Officer of Tilray Brands, Inc. He has extensive experience in the consumer packaged goods industry, having previously served as the Chairman and CEO of Hain Celestial Group, Inc., a leading organic and natural products company. Simon has a proven track record of building and growing successful consumer brands. He holds a Bachelor of Science degree in Business Administration from Concordia University.
Track Record: Under Irwin Simon's leadership, Tilray Brands has focused on strategic acquisitions and diversification to expand its presence in the cannabis, beverage alcohol, and wellness markets. He has overseen the integration of Aphria and Tilray, creating a global cannabis leader. Simon has also emphasized innovation and product development to cater to evolving consumer preferences.
What Investors Ask About Tilray Brands, Inc. (TLRY) — Healthcare
What does the AI Score mean for TLRY?
TLRY holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Tilray Brands, Inc. is a global cannabis-lifestyle CPG company. The company cultivates, produces, markets, and distributes medical and adult-use cannabis, along with beverage alcohol and wellness …
What does Tilray Brands, Inc. do?
Tilray Brands, Inc. is a global cannabis-lifestyle CPG company that researches, cultivates, produces, markets, and distributes medical and adult-use cannabis products. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business.
What do analysts say about TLRY stock?
Analyst coverage of Tilray Brands, Inc. (TLRY) is mixed, reflecting the uncertainties and growth opportunities within the cannabis industry. Key valuation metrics, such as price-to-sales and price-to-book ratios, are often considered in relation to the company's growth prospects.
What are the main risks for TLRY?
Tilray Brands faces several key risks, including regulatory uncertainty in the cannabis industry, which can impact its ability to operate and expand in certain markets. Intense competition from other cannabis companies and beverage alcohol producers can put pressure on pricing and market share. Fluctuations in cannabis prices and demand can affect the company's revenue and profitability.
What are the key factors to evaluate for TLRY?
Tilray Brands, Inc. (TLRY) holds an AI score of 47/100 (low). Analysts target $10.00 (+114%). presents a multifaceted investment thesis predicated on its diversified business model and strategic positioning within the evolving cannabis and consumer packaged goods industries. Not financial advice.
How frequently does TLRY data refresh on this page?
TLRY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TLRY's recent stock price performance?
Tilray Brands, Inc. (TLRY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified business model across cannabis, beverage alcohol, and wellness. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TLRY overvalued or undervalued right now?
Tilray Brands, Inc. (TLRY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $10.00 (+114%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TLRY before investing?
Before investing in Tilray Brands, Inc. (TLRY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The cannabis industry is subject to rapid regulatory changes, which could impact the company's operations and financial performance.
- The company's future performance is dependent on its ability to successfully execute its growth strategy and manage its costs.